Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018

Dongdong Lin, Ming Wang, Yan Chen, Jie Gong, Liang Chen, Xiaoyong Shi, Fujun Lan, Zhongliang Chen, Tao Xiong, Hu Sun and Shu Wan*

Brain Center, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China

Purpose: Glioma incidence in the US seems to have stabilized over the past 20 years. It’s also not clear whether changes in glioblastoma incidence are associated with glioma mortality trends. Our study investigated trends in glioma incidence and mortality according to tumor characteristics.

Methods: This study obtained data from the Surveillance, Epidemiology, and End Results-9 (SEER-9) registries to calculate glioma incidence and mortality trends. Annual percent changes (APC) and 95% CIs were calculated using the Joinpoint program.

Results: 62,159 patients (34,996 males and 55,424 whites) were diagnosed with glioma during 1975-2018, and 31,922 deaths occurred from 1995-2018. Glioblastoma (32,893 cases) and non-glioblastoma astrocytoma (17,406 cases) were the most common histologic types. During the study period, the incidence of glioma first experienced a significant increase (APC=1.8%, [95% CI, 1.3% to 2.3%]) from 1975 to 1987, and then experienced a slight decrease (APC=-0.4%, [95% CI, -0.5% to -0.3%]) from 1987 to 2018, while the APC was 0.8% for glioblastoma, -2.0% for non-glioblastoma astrocytoma, 1.1% for oligodendrogial tumors, 0.7% for ependymoma and -0.3% for glioma NOS during the study period. Glioblastoma incidence increased for all tumor size and tumor extension except for distant. From 1995 to 2018, glioma mortality declined 0.4% per year (95% CI: -0.6% to -0.2%) but only increased in patients older than 80 years [APC=1.0%, (95% CI, 0.4% to 1.6%)].

Conclusion: Significant decline in glioma incidence (1987-2018) and mortality (1995-2018) were observed. Epidemiological changes in non-glioblastoma astrocytoma contributed the most to overall trends in glioma incidence and mortality. These findings can improve understanding of risk factors and guide the focus of glioma therapy.

Keywords: glioma, glioblastoma, trends, age-adjusted incidence, incidence-based mortality, relative survival
INTRODUCTION

According to the latest cancer statistics report (1), the United States is expected to have 23,890 cases diagnosed with brain and other nervous system tumors, and 18,020 deaths in 2020. It has become the leading cause of cancer death among males aged birth to 39 years and females aged birth to 19 years. Malignant glioma is a devastating type of brain and other nervous system tumors because of its high malignancy, extremely high mortality rate, and recurrence risk, as well as the huge burden on society and families (2). It is responsible for most deaths of patients with primary brain tumors. The incidence and mortality of glioma increase significantly with advancing age. With the aging trend of American society, the burden associated with glioma may become a huge challenge.

Although no population-based global epidemiological survey of glioma has been reported, the incidence of glioma varies geographically. The incidence of glioma in the American and northern European populations was higher than that in the Asian population, reaching about 2 times (3). Regions also showed different incidence trends. A Japanese study reported that the incidence rate of malignant glioma has risen significantly among the elderly from 1989 to 2008 (4), while CBTRUS reported that the incidence of glioma in people over 40 years old in the US was relatively stable from 2000 to 2016 (2). Besides, glioma incidence varies significantly by age, sex, race (5), and other factors. Compared with the relatively low incidence of glioma, the annual number of deaths caused by glioma deserves people’s attention. The mortality rate is a convincing indicator to reflect the progress against glioma. However, few studies have focused on the mortality of glioma.

Because glioblastoma accounts for the majority of glioma (57.3%) and its 5-year survival rate is only 6.8% after diagnosed (1), it provides an impression that changes in its epidemiological data may reflect the incidence and mortality of glioma. To clarify this issue, the current study quantified the differences in glioma incidence and mortality trends based on demographic and tumor characteristics, and further compared them with glioblastoma.

METHODS

Data Sources

Information on glioma incidence was extracted from the SEER-9 incidence database (6), containing cases from nine high-quality registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta), which covers approximately 9.4% of the U.S. population. Though the SEER database contains cases diagnosed starting with 1973, the Seattle and Atlanta registries joined the SEER program in 1974 and 1975, respectively. So, we calculated incidence rates for cases diagnosed between 1975-2018, the only years for which all 9 registries have cases in the database.

The SEER-9 incidence-based mortality database (7) provides a convenient, intuitive mechanism to analyze glioma mortality derived from information recorded on death certificates. Different from general mortality rates, the incidence-based mortality rates allow for a breakdown of mortality rates by variables associated with cancer onset. In our study, we calculated incidence-based mortality rates for patients who died during 1995-2018 and were diagnosed during 1975-2018 to guarantee as many deaths as possible and to reduce underestimation of early incidence-based mortality rates.

Relative survival was analyzed using the SEER-9 incidence database (6). It is defined as the ratio of observed survivors (all causes of death) in a group of cancer patients to the expected survivors in a group of non-cancer patients (8). One- to ten-years relative survival rates for glioma and glioblastoma diagnosed in different years were compared.

Patients’ Characteristics

Patients’ Characteristics of this study included demographic and tumor characteristics, obtained from medical records and death certificates respectively. Demographic characteristics used in this study were sex, race, age groups at diagnosis/death (younger than 20, 20-39, 40-59, 60-79, and 80 years or older), median household income ($/year) and rural-urban distribution.

Histologic types were classified according to codes of International Classification of Diseases for Oncology, Third Edition (ICD-O-3), and were grouped into glioblastoma, non-glioblastoma astrocytoma, oligodendrogial tumors, ependymoma, and gliomas NOS (eTable 1 in the Supplement data) following the classification criterion of CBTRUS (the Central Brain Tumor Registry of the United States). Only tumors located in the brain (ICD-O-3 topography code C71) and malignant behavior (ICD-O-3 behavior code of/3) were included. Due to the lack of WHO grade in the SEER database, we defined glioma WHO grade according to the 2007 WHO Classification of Tumours of the Central Nervous System (9) (eTable 2 in the Supplement data).

Four different sets of codes from 1983: Extent of Disease-4 codes (EOD-4) for 1983-1987, Extent of Disease-10 codes (EOD-10) for 1988-2003, Collaborative Staging codes (CS) for 2004-2015 and Tumor Size Summary for 2016+, were merged to define tumor extension and size. Tumor extension was divided into localized, regional, distant, and unknown stages.

Data Analysis

Glioma incidence and mortality rates were generated by SEER*Stat version 8.3.9 and reported as per 100,000 person-years. All rates were age-adjusted to the 2000 US standard population and rate ratios were calculated based on these standardized rates. Rate ratios were used to assess the degree of change for glioma with histologic type, tumor extension, or size, as well as the impact of unknown variables.

Joinpoint Regression Program, version 4.7.0.0, was used to evaluate the trends of incidence and mortality and calculated annual percentage change (APC) and 95% CIs. This program takes trend data and fits the simplest joinpoint model that the data allow. It tests that an apparent change in trend is statistically significant using a Monte Carlo Permutation method (10).

A two-sided P value of 0.05 was considered statistically significant.
RESULTS

During 1975-2018, 62,159 cases diagnosed as glioma in the states recorded by SEER-9 were included in the incidence analysis (Table 1). Men (34,996 [56.3%]) and white cases (55,424 [89.2%]) constituted the principal part of the patients. Among them, glioblastoma (32,893 [52.9%]) and non-glioblastoma astrocytoma (17,406 [28.0%]) were the two most common histological types. The occurrence of glioma was mainly concentrated in the middle-aged and elderly population. Additionally, incidence-based mortality analysis revealed 31,922 patients with glioma died from 1995-2018. Of the deaths, 18,322 (57.4%) cases were men and 28,297 (88.6%) cases were white patients. Among those who died, patients tended to be older, diagnosed with glioblastoma, and with a localized or larger tumor.

Among all glioma patients in the study, we were unable to obtain information on tumor extension in approximately 21.6% of patients who were diagnosed before 1983 and after 2015 and the proportion in glioblastoma was 21.2%. There were also 13.0% of glioma patients and 10.7% of glioblastoma patients lacking tumor size information because the diagnosis was before 1983. Of the deaths during 1995-2018, 15.9% of glioma patients were diagnosed before 1983 and after 2015 with no information on tumor extension and the proportion in glioblastoma was 16%. 1.3% of glioma deaths and 0.1% of glioblastoma deaths were diagnosed before 1983 and lack of tumor size information. In the years that we can get information about tumor characteristics, WHO grade was unknown for 7.6% of glioma patients and 6.3% of deaths, tumor extension was unknown for 6.8% of glioma patients and 6.0% for deaths, and tumor size was unknown for 39.2% of glioma patients and 32.3% of deaths.

According to demographic and glioma characteristics, trends in glioma incidence was showed in Figure 1 and Table 2. Joinpoint program divided the trends into a minimum of 1 to a maximum of 5. During the entire study period, glioma incidence did not change significantly (APC=0.0), but its incidence increased significantly from 1975 to 1987 (APC=1.8%, [95% CI, 1.3% to 2.3%]), and decreased significantly from 1987 to 2018 (APC=-0.4%, [95% CI, -0.5% to -0.3%]). Glioma incidence in male was 1.47 times higher than that in female, and the difference increased with age (from 1.08 [95% CI: 1.02 to 1.13] times in those younger than 20 to 1.67 [95% CI: 1.58 to 1.77] times in those older than 80) (eTable 3 in the Supplement data). The difference in glioblastoma incidence between male and female was more significant. But both incidence trends were similar to the overall trend. Glioma incidence increased for whites, patients younger than 20 years or older than 80 years, while it decreased in the population aged 40-59 years. From 1990 to 2018, there were significantly decreasing incidence trends in both high- or low-income families and urban or rural patients. In terms of glioma histology, positive trends were observed for glioblastoma (APC=0.8%, [95% CI, 0.6% to 1.0%]), oligodendrogial tumor (APC=1.1%, [95% CI, 0.2% to 2.1%]) and ependymoma (APC=0.7%, [95% CI, 0.3% to 1.1%]), while non-glioblastoma astrocytoma (APC=-2.0%, [95% CI, -2.4% to -1.6%]) showed downward trends. Glioblastoma incidence increased by 2.9% (95% CI, 2.1% to 3.8%) per year from 1978 to 1992, but it slowed down during 1992-2018 (APC=0.2%, [95% CI, 0.0% to 0.5%]). Glioblastoma incidence increased significantly for all tumor size and extension groups except that the number of patients with distant metastases was too rare to reach statistical scope.

In the earliest years of the initial inclusion of cases, glioma incidence-based mortality rates may be underestimated. Therefore, we left a buffer time of 20 years to calculate the glioma mortality trends from 1995 to 2018 (Figure 2 and Table 3). During this period, glioma incidence-based mortality rate decreased 0.4% (95% CI, -0.6% to -0.2%) per year averagely. Most demographic groups had negative APC with statistical difference, such as patients who were both genders, white, and diagnosed between 20 and 79 years old. It was worth noting that only patients older than 80 years showed a significant increase in incidence-based mortality (APC=1.0%, [95% CI, 0.4% to 1.6%]). There were also significant differences in mortality between male and female. The mortality rate of men was about 1.58 times than that of women, and among those over 80 years old, the proportion reached 1.67 (95% CI: 1.57 to 1.77) (eTable 3 in the Supplement data). Interestingly, high-income patients showed a significant decrease in mortality (APC=-1.6%, [95% CI, -2.2% to -1.0%]), while low-income patients showed a significant increase in mortality (APC=1.1%, [95% CI, 0.6% to 1.6%]). By glioma histology, non-glioblastoma astrocytoma (APC=-2.1%, [95% CI, -2.6% to -1.5%]) and glioma NOS (APC=-1.0%, [95% CI, -1.8% to -0.2%]) exhibited significantly reduced mortality rates, while the mortality rates of glioblastoma, oligodendrogial tumor and ependymoma were relatively stable during this period. Additionally, only glioma patients with WHO grade II had a significant decrease (APC=-2.0%, [95% CI, -2.5% to -1.6%]) in incidence-based mortality among patients with known WHO grade. Significantly positive APC occurred for glioblastoma patients of localized tumor at diagnosis (APC=0.5%, [95% CI, 0.2% to 0.7%]). Glioblastomas of all known size showed significant increases in incidence-based mortality.

Survival analysis (eTable 4 in the Supplement data) revealed that relative survival rates for glioma and glioblastoma increased with the year of diagnosis. The 1-year relative survival rate of glioma patients increased from 39.24% for cases diagnosed between 1975-1979 to 58.40% for cases diagnosed in 2017, while the 5-year relative survival rate increased from 14.84% for cases diagnosed between 1975-1979 to 27.25% for cases diagnosed in 2013. Besides, the 1-year relative survival rate of glioblastoma patients also increased from 26.18% for cases diagnosed between 1975-1979 to 44.90% for those diagnosed in 2017. Its 5-year relative survival rate peaked at 6.86% among the cases diagnosed in 2005 and has remained at a high level since then.

Rate Ratios were calculated for all glioma histologic types and glioblastoma by known and unknown variables of tumor extension and tumor size (Tables 5 and 6 in the Supplement data). The incidence rate for glioblastoma with unknown
TABLE 1 | Glioma Incidence (1975-2018) and Incidence-Based Mortality (1995-2018): the SEER-9 registry database.

| Characteristic | Incidence | Incidence-Based Mortality |
|----------------|-----------|---------------------------|
|                | Glioma    | Glioblastoma              | Glioma | Glioblastoma |
|                | Cases, No. (%) | Rate (95% CI)* | Cases, No. (%) | Rate (95% CI)* | Deaths, No. (%) | Rate (95% CI)* | Deaths, No. (%) | Rate (95% CI)* |
| Overall        | 62159     | 5.60 (5.56-5.65)         | 32986  | 2.99 (2.96-3.02) | 31922  | 4.59 (4.54-4.64) | 21201  | 3.04 (3.00-3.08) |
| Sex            |           |                          |        |                  |        |                  |        |                  |
| Male           | 34996 (56.3) | 6.78 (6.71-6.85) | 19009  | 3.80 (3.78-3.85) | 18322  | 5.74 (5.65-5.82) | 12281  | 3.87 (3.80-3.94) |
| Female         | 27163 (43.7) | 4.61 (4.56-4.67) | 13977  | 2.33 (2.29-2.37) | 13600  | 3.63 (3.57-3.69) | 8920 (42.1) | 2.35 (2.30-2.40) |
| Race           |           |                          |        |                  |        |                  |        |                  |
| White          | 55424 (89.2) | 6.22 (6.17-6.28) | 29920  | 3.32 (3.28-3.36) | 28297  | 5.15 (5.09-5.21) | 18992  | 3.42 (3.37-3.47) |
| Black          | 3646 (5.9)  | 3.25 (3.14-3.36) | 1727 (5.2) | 1.64 (1.56-1.73) | 1858 (6.8) | 2.68 (2.56-2.81) | 1123 (5.3) | 1.71 (1.61-1.82) |
| Otherc         | 3089 (5.0)  | 2.79 (2.69-2.89) | 1426 (4.3) | 1.36 (1.29-1.44) | 1767 (5.5) | 2.24 (2.14-2.35) | 1086 (5.1) | 1.40 (1.32-1.49) |
| Age at Diagnosis/Death, y | | | | | | | | |
| <20            | 6099 (9.8)  | 1.90 (1.86-1.95) | 434 (1.3)  | 0.14 (0.12-0.15) | 926 (2.9)  | 0.51 (0.47-0.54) | 188 (0.9)  | 0.10 (0.09-0.12) |
| 20-39          | 9035 (14.5) | 2.68 (2.62-2.74) | 1793 (5.4) | 0.55 (0.52-0.57) | 2284 (7.2) | 1.21 (1.16-1.26) | 724 (3.4)  | 0.39 (0.36-0.42) |
| 40-59          | 18163 (29.2) | 6.34 (6.24-6.43) | 10231 (31.0) | 3.50 (3.44-3.57) | 9642 (30.2) | 5.05 (4.95-5.15) | 5968 (28.1) | 3.08 (3.00-3.16) |
| 60-79          | 23987 (38.6) | 16.21 (16.00-16.42) | 17062 (51.7) | 11.56 (11.39-11.74) | 14989 (47.0) | 16.47 (16.21-16.74) | 11336 | 12.49 (12.26-12.73) |
| ≥80            | 4875 (7.8)  | 14.42 (14.00-14.83) | 3466 (10.5) | 10.25 (9.92-10.60) | 4081 (12.8) | 17.81 (17.26-18.36) | 2985 (14.1) | 13.05 (12.59-13.53) |
| Median Household Income, $/year (1990-2018) | | | | | | | | |
| <75000         | 25019 (55.2) | 5.62 (5.55-5.69) | 14098 (54.8) | 3.14 (3.09-3.19) | 17002 (55.4) | 2.44 (2.41-2.48) | 11615 (55.0) | 1.66 (1.63-1.69) |
| ≥75000         | 20307 (44.8) | 5.62 (5.55-5.70) | 11650 (45.2) | 3.21 (3.15-3.27) | 13710 (44.6) | 1.97 (1.94-2.01) | 9513 (45.0) | 1.36 (1.34-1.39) |
| Rural-Urban Distribution (1990-2018) | | | | | | | | |
| Urban          | 39043 (86.9) | 5.64 (5.59-5.70) | 22116 (86.6) | 3.20 (3.16-3.24) | 26328 (86.4) | 3.79 (3.74-3.83) | 18186 (86.4) | 2.60 (2.57-2.64) |
| Rural          | 5867 (13.1)  | 5.68 (5.53-5.83) | 3431 (13.4)  | 3.13 (3.02-3.24) | 4130 (13.6)  | 0.60 (0.58-0.62) | 2808 (13.4)  | 0.40 (0.39-0.42) |
| Histologic Type | | | | | | | | |
| Glioblastoma   | 32893 (52.9) | 2.98 (2.95-3.01) | 21123 (66.2) | 3.03 (2.99-3.07) | 5903 (18.2) | 0.84 (0.82-0.86) | 32893 (52.9) | 2.98 (2.95-3.01) |
| Non-glioblastoma astrocytoma | 17406 (28.0) | 1.55 (1.53-1.58) | 2641 (8.3)  | 0.38 (0.37-0.39) | 453 (1.4)  | 0.07 (0.06-0.07) | 453 (1.4)  | 0.07 (0.06-0.07) |
| Oligodendroglial tumors | 5789 (9.3)  | 0.52 (0.51-0.53) | 1902 (6.0)  | 0.28 (0.27-0.29) | 1902 (6.0)  | 0.28 (0.27-0.29) | 1902 (6.0)  | 0.28 (0.27-0.29) |
| Ependymoma     | 1474 (2.4)  | 0.13 (0.12-0.14) | 453 (1.4)  | 0.07 (0.06-0.07) | 453 (1.4)  | 0.07 (0.06-0.07) | 453 (1.4)  | 0.07 (0.06-0.07) |
| Glioma, NOS    | 4598 (7.4)  | 0.42 (0.41-0.43) | 1902 (6.0)  | 0.28 (0.27-0.29) | 1902 (6.0)  | 0.28 (0.27-0.29) | 1902 (6.0)  | 0.28 (0.27-0.29) |
| WHO Grade      | | | | | | | | |
| I              | NRd | NRd | NRd | NRd | NRd | NRd | NRd | NRd |
| II             | 19292 (31.0) | 1.72 (1.70-1.74) | 6016 (18.8) | 0.87 (0.85-0.89) | 6016 (18.8) | 0.87 (0.85-0.89) | 6016 (18.8) | 0.87 (0.85-0.89) |

(Continued)
| Characteristic                  | Incidence | Incidence-Based Mortality |
|-------------------------------|-----------|---------------------------|
|                               | Glioma    | Glioblastoma              |
|                               | Incidence | Incidence-Based Mortality |
|                               | Cases, No. (%) | Rate (95% CI)* | Deaths, No. (%) | Rate (95% CI)* |
| III                           | 5242 (8.4) | 0.47 (0.46-0.48) | 2785 (8.7) | 0.40 (0.39-0.42) |
| IV                            | 32893 (52.9) | 2.98 (2.95-3.01) | 21123 (66.2) | 3.03 (2.99-3.07) |
| Unknown                       | 4729 (7.6) | 0.43 (0.42-0.44) | 1997 (6.3) | 0.29 (0.28-0.31) |

| Tumor Extension (1983-2015)    |           |                           |
| Stable                        | 37142 (76.2) | 4.35 (4.30-4.39) | 20187 (75.2) | 3.42 (3.37-3.47) |
| Localized                     | 8089 (16.6) | 0.95 (0.93-0.97) | 4984 (18.6) | 0.84 (0.82-0.87) |
| Regional                      | 208 (0.4) | 0.02 (0.02-0.03) | 85 (0.3) | 0.02 (0.01-0.02) |
| Distant                       | 3296 (6.8) | 0.39 (0.38-0.41) | 1605 (6.0) | 0.28 (0.26-0.29) |
| Unknown                       |           |                           |

| Tumor size, cm (1983-2018)    |           |                           |
| ≤3.0                          | 8972 (16.6) | 0.94 (0.92-0.96) | 5152 (16.3) | 0.74 (0.72-0.76) |
| >3.0 to ≤5.0                  | 13761 (25.4) | 1.44 (1.42-1.46) | 9225 (29.3) | 1.33 (1.30-1.35) |
| >5.0                          | 10160 (18.8) | 1.06 (1.04-1.08) | 6975 (22.1) | 1.00 (0.98-1.02) |
| Unknown                       | 21168 (39.2) | 2.22 (2.19-2.25) | 9488 (32.2) | 1.00 (0.98-1.02) |

*Rates were calculated as number of cases or deaths per 100,000 person-years and age-adjusted to the 2000 US standard population.

aNumber of deaths were based on cases diagnosed during 1975-2018.

bIncludes American Indian/Alaskan Native and Asian/Pacific Islander.

cStatistical suppressed because of fewer than 16 cases or deaths.

SEER, Surveillance, Epidemiology, and End Results; NOS, Not otherwise specified; WHO, World Health Organization.
tumor extension decreased from 1983-1987 to 2012-2015 by 0.54 (95% CI: 0.44 to 0.66) times, meaning that the observed increase in glioblastoma with known tumor extension was overestimated. Glioblastoma with unknown tumor size declined from 1983-1987 to 2013-2018 by 0.28 (95% CI: 0.25 to 0.30) times, indicating that the observed increase in glioblastoma with known tumor size was overestimated. Additionally, the mortality rate for glioblastoma with unknown tumor extension declined by 0.47 (95% CI: 0.39 to 0.57) times from 1995-1998 to 2011-2015, suggesting that glioblastoma deaths with known tumor extension were overestimated. The mortality rate for glioblastoma with unknown tumor size decreased by 0.35 (95% CI: 0.32 to 0.39) times from 1995-1998 to 2015-2018, meaning that the increase in the mortality rate for glioblastoma with known tumor size was overestimated.

**DISCUSSION**

The present study is the first to report intracranial glioma mortality trends in the United States. Incidence and mortality trends were compared systematically according to demographic and tumor characteristics. We also conducted a detailed analysis of the epidemiological trends for glioblastoma. The main finding was the significant decline in the age-adjusted incidence of glioma from 1987 to 2018 (APC=-0.4%, [95% CI, -0.5% to -0.3%]) and the incidence-based mortality from 1995 to 2018 (APC=-0.4%, [95% CI, -0.6% to -0.2%]). This finding is inconsistent with the significantly increased incidence and stable mortality of glioblastoma and appears to be related to the trends of non-glioblastoma astrocytoma.

The epidemiological studies of glioma published in recent years were presented in Table 4. There were differences in cancer registries, study years and design. According to the report, glioma incidence ranged from 4.80 to 7.70 per 100,000 person-years, while the incidence of glioblastoma ranged from 2.82 to 5.10 per 100,000 person-years. Glioma incidence of our study was 5.60 (5.56-5.65) per 100,000 person-years and that of glioblastoma was 2.99 (2.96-3.02) per 100,000 person-years. They were consistent with incidence reported in other US studies and lower than those reported in Nordic countries. However, there are few reports on glioma mortality.

Trends in the incidence rates are an effective measure for assessing the burden of disease in a specific population. We used the latest available data to analyze the 44-year incidence rates in parts of the United States. Over time, many factors could cause fluctuations in incidence rates. We strove to find significant trends in incidence over a certain period of this study and interpret the result. Joinpoint program analyzed
TABLE 2 | Trends in Glioma Incidence Ratesa (1975-2018): the SEER-9 registry database

| Characteristic | Overall (1975-2018) | | | | Trendsb | | | |
|---------------|----------------------|---|---|---|---|---|---|---|---|
|               | APC (95%CI) | P Value | Year | APC (95%CI) | P Value | Year | APC (97%CI) | P Value | Year | APC (98%CI) | P Value |
|---------------|-------------|----------|------|-------------|----------|------|-------------|----------|------|-------------|----------|
| Overall       | 0.0 (-0.2 to 0.1) | 0.581 | 1975-1987 | 1.8 (1.3 to 2.3) | <.001 | 1987-2018 | -0.4 (0.5 to -0.3) | <.001 |
| Sex           | Female      | 0.0 (-0.2 to 0.2) | 0.988 | 1975-1986 | 2.1 (1.3 to 3.0) | <.001 | 1986-2013 | -0.3 (0.4 to -0.1) | 0.007 | 2013-2018 | -1.8 (-3.8 to 0.3) | 0.090 |
|               | Male        | -0.1 (-0.2 to 0.0) | 0.205 | 1975-1987 | 1.6 (0.9 to 2.3) | <.001 | 1987-2018 | -0.4 (0.6 to -0.3) | <.001 |
| Race          | White       | 0.1 (0.0 to 0.3) | 0.034 | 1975-1987 | 1.9 (1.4 to 2.5) | <.001 | 1987-2018 | -0.2 (0.3 to -0.1) | 0.001 |
|               | Black       | 0.0 (-0.3 to 0.3) | 0.825 | 1975-1995 | 2.0 (1.0 to 3.1) | <.001 | 1995-2018 | -0.5 (-0.9 to 0.0) | 0.054 |
|               | Otherc      | 0.3 (0.0 to 0.6) | 0.041 | 1975-1995 | 2.0 (1.0 to 3.1) | <.001 | 1995-2018 | -0.5 (-0.9 to 0.0) | 0.054 |
| Age at Diagnosis, y | <20      | 0.4 (0.1 to 0.8) | 0.014 | 1975-1988 | 2.9 (0.9 to 4.9) | 0.005 | 1988-2018 | -0.2 (0.7 to 0.3) | 0.477 |
|               | 20-39       | 0.1 (-0.2 to 0.3) | 0.662 | 1975-1986 | 1.9 (0.0 to 3.8) | 0.047 | 1986-2018 | -0.2 (-0.6 to 0.1) | 0.127 |
|               | 40-59       | -0.6 (-0.7 to -0.5) | <.001 | 1975-1981 | 2.0 (0.7 to 4.8) | 0.145 | 1981-2018 | -0.7 (-0.9 to -0.6) | <.001 |
|               | 60-79       | -0.1 (-0.2 to 0.1) | 0.444 | 1975-1987 | 1.9 (1.1 to 2.8) | <.001 | 1987-2018 | -0.4 (-0.6 to -0.3) | <.001 |
|               | ≥80         | 1.4 (1.0 to 1.8) | <.001 | 1975-1985 | 9.0 (4.2 to 14.0) | <.001 | 1985-2018 | 0.8 (0.4 to 1.2) | <.001 |

Median Household Income (1990-2018)

|                   | <75000 | -0.3 (-0.5 to -0.2) | <.001 | ≥75000 | -0.4 (-0.5 to -0.2) | <.001 |

Rural-Urban (1990-2018)

|                   | Urban | -0.5 (-0.6 to -0.3) | <.001 | Rural | -0.4 (-0.7 to 0.0) | 0.031 |

Histologic Type

|                   | Glioblastoma | 0.8 (0.6 to 1.0) | <.001 | 1975-1978 | -11.9 (-18.9 to -4.3) | 0.004 | 1978-1992 | 2.9 (2.1 to 3.6) | <.001 | 1992-2018 | 0.2 (0.0 to 0.5) | 0.038 |
|                   | Non-glioblastoma | -2.0 (-2.4 to -1.6) | <.001 | 1975-1977 | -49.8 (23.3 to 0.0) | <.001 | 1977-1987 | 1.1 (-0.2 to 2.3) | 0.092 | 1987-2018 | -5.8 (6.8 to -4.7) | <.001 |
|                   | Astrocytoma | 1.1 (0.2 to 2.1) | 0.020 | 1973-1997 | 6.1 (0.3 to 6.8) | <.001 | 1997-2012 | -2.9 (-4.2 to -1.7) | <.001 | 2012-2018 | -8.3 (-12.4 to -4.1) | <.001 |
|                   | Oligodendroglial tumors | 0.7 (0.3 to 1.1) | 0.001 | 1975-1988 | 1.5 (-0.1 to 3.1) | 0.063 | 1988-1991 | -10.8 (33.0 to 18.9) | 0.427 | 1991-2018 | 0.6 (0.1 to 1.1) | 0.016 |

WHO Grade

|                   | I | NRd |

(Continued)
### TABLE 2 | Continued

| Characteristic | Overall (1975-2018) | 1 | 2 | 3 | 4 | 5 |
|----------------|---------------------|---|---|---|---|---|
|                | APC (95%CI)         | P Value | Year | APC (95%CI) | P Value | Year | APC (96%CI) | P Value | Year | APC (97%CI) | P Value | Year | APC (98%CI) | P Value |
| II             | -2.1 (-2.4 to -1.7) | <.001 | 1975 | 42.1 (18.6 to 77.2 | <.001 | 1977 | 0.6 (0 to 1.2) | 0.335 | 1987 | -6.3 (-10.1 to -2.2) | 0.004 | 1992 | -1.7 (-2.1 to -1.2) | <.001 |
|                |                     |        | 1977 | 70.2            |        | 1987 |                    |        | 2008 | 3.5 (0.9 to 6.2) | 0.009 |        |                          |        |
| III            | 2.2 (1.5 to 2.9)    | <.001 | 1975 | 12.1 (8.9 to 15.4 | <.001 | 1990 | -0.4 (-1.7 to 1.0) | 0.594 | 2008 | 2.9 (2.1 to 3.8) | <.001 | 1992 | 0.2 (0.0 to 0.5) | 0.038 |
|                |                     |        | 1990 | 15.4            |        | 2008 |                    |        | 1992 |                    |        |        |                          |        |
| IV             | 0.8 (0.6 to 1.0)    | <.001 | 1975 | -11.9 (-18.9 to -4.3 | 0.004 | 1978 | 2.9 (2.1 to 3.8) | <.001 | 1991 | 0.6 (1.1 to 1.1) | 0.014 |        |                          |        |
|                |                     |        | 1978 | -14.2           |        | 1991 |                    |        | 1992 |                    |        |        |                          |        |
| Unknown        | -0.2 (-0.5 to 0.1)  | 0.125  | 1975 | 1.4 (-0.2 to 3.0) | 0.076 | 1988 | -9.9 (-31.9 to 19.3) | 0.458 | 1991 |                    |        |        |                          |        |
|                |                     |        | 1978 | 3.0             |        | 1991 |                    |        | 1992 |                    |        |        |                          |        |

**Glioblastoma**

**Tumor Extension (1983-2015)**

|                | Overall (1983-2015) | 1 | 2 | 3 | 4 | 5 |
|----------------|---------------------|---|---|---|---|---|
|                | APC (95%CI)         | P Value | Year | APC (95%CI) | P Value | Year | APC (95%CI) | P Value | Year | APC (95%CI) | P Value |
| Localized      | 1.0 (0.8 to 1.2)    | <.001 | 1983 | 1.4 (1.0 to 1.8) | <.001 | 2005 | -0.1 (1.0 to 0.9) | 0.857 |        |                          |        |
|                |                     |        | 2005 | 1.8             |        | 2015 |                    |        |        |                          |        |
| Regional       | 1.5 (1.0 to 2.0)    | <.001 | 1983 | 7.4 (2.8 to 12.2) | 0.002 | 1991 | 0.7 (0.1 to 1.3) | 0.020 |        |                          |        |
|                |                     |        | 1991 | 12.2            |        | 2015 |                    |        |        |                          |        |
| Distant        | NR<sup>b</sup>      |        |        |                |        |        |                          |        |        |                          |        |
| Unknown        | -3.3 (-4.2 to -2.3) | <.001 | 1983 | 3.9 (0.5 to 7.4) | 0.027 | 1993 | -7.5 (-9.6 to -5.4) | <.001 | 2008 | 5.0 (2.0 to 12.6) | 0.158 |        |                          |        |
|                |                     |        | 1993 | 3.0             |        | 2015 |                    |        |        |                          |        |

**Tumor size, cm (1983-2018)**

|                | Overall (1983-2018) | 1 | 2 | 3 | 4 | 5 |
|----------------|---------------------|---|---|---|---|---|
| ≤3.0           | 2.6 (2.0 to 3.1)    | <.001 | 1983 | 9.3 (4.6 to 14.2) | <.001 | 1992 | 1.8 (1.3 to 2.4) | <.001 |        |                          |        |
|                |                     |        | 1992 | 14.2            |        | 2018 |                    |        |        |                          |        |
| >3.0 to ≤5.0   | 2.8 (2.2 to 3.4)    | <.001 | 1983 | 14.0 (10.1 to 18.1) | <.001 | 1991 | 3.4 (2.5 to 4.3) | <.001 | 2006 | 0.1 (-0.8 to 1.0) | 0.803 |        |                          |        |
|                |                     |        | 1991 | 18.1            |        | 2018 |                    |        |        |                          |        |
| >5.0           | 4.3 (3.6 to 5.0)    | <.001 | 1983 | 6.7 (4.1 to 9.4) | <.001 | 2007 | 0.1 (-1.0 to 1.2) | 0.855 |        |                          |        |
|                |                     |        | 2007 | 5.0             |        | 2018 |                    |        |        |                          |        |
| Unknown        | -4.3 (-4.8 to -3.9) | <.001 | 1983 | -0.7 (-3.2 to 1.8) | 0.566 | 1992 | -5.3 (-5.9 to -4.6) | <.001 |        |                          |        |
|                |                     |        | 1992 | 1.8             |        | 2018 |                    |        |        |                          |        |

* Rates were calculated as number of cases or deaths per 100,000 person-years and age-adjusted to the 2000 US standard population.  
* Each segment was defined by the joinpoint program when a statistically significant change in the APC occurred.  
* Includes American Indian/Alaskan Native and Asian/Pacific Islander.  
* APC could not be calculated because there were 0 case in one or more years.  
* SEER, Surveillance, Epidemiology, and End Results; APC, annual percent change; NOS, Not otherwise specified; WHO, World Health Organization.
that the incidence of glioma experienced a significant increase before 1987, and then began to slowly decline. The early increase in incidence was partly attributed to the improvement of diagnostic technology, especially the introduction of CT in the 1970s and MRI in the 1980s. The advancement and increasingly widespread use of imaging diagnostic technology may detect subtle or small brain glioma, and more patients with asymptomatic or only mild symptoms were found (20, 21). Our results also showed that the incidence of tumors (both glioma and glioblastoma) smaller than 3cm continued to increase throughout the study period. This factor may also contribute to the rapid increase in the incidence of glioblastoma by 2.9% per year from 1978 to 1992. Additionally, the early 9 SEER registries to improve cancer registration procedures may affect glioma incidence statistics.

With the popularization of glioma diagnosis methods, its rapidly increasing incidence rate began to decelerate and has continued to decline since 1987. However, the glioblastoma incidence trend was different, with a significant increase of 0.2% per year after 1992. Thus, changes in the use of cancer screening tests are not solely responsible for the incidence trends. Behaviors related to cancer risk are a small but actual factor that affects glioma incidence. Numerous studies have been conducted to investigate the environmental and behavioral risk factors for glioma. Only ionizing radiation is a well-validated factor that increases the risk of glioma (22).

Two studies about children exposed to low-dose diagnostic radiation tests revealed suffering CT scans in childhood increases the risk of brain tumors in adulthood, but the incidence was extremely low, only one excess case of brain tumor per 10,000 head CT scans in the 10 years after the first CT scan (23, 24). Additional risk research found that patients receiving high-dose radiation therapy increase the risk of glioma (25). Yet, the concern is that medical radiation has indeed increased significantly (26) over the past 20 years, despite the clinical benefits outweigh the risks (27). Mobile phone use has also caused public health concerns about the risk of occurrence of glioma because the brain is the organ most affected by the radiofrequency field of mobile phone. Several epidemiological studies on mobile phone use and increased risk of glioma cannot reach valid conclusions (28, 29). In addition, occupational exposure and chemical agents have also been checked, with no evidence related to the risk of glioma (30, 31).

There is growing epidemiological evidence consistently suggesting that atopic diseases, such as allergies, asthma, eczema, etc. reduce the risk of glioma (32–35). Related research revealed that when the subject is in atopic conditions, the risk of glioma is reduced by 30–40% (36, 37). Interestingly, as the types of allergies and the duration of symptoms increase, the risk of glioma is further reduced (38). The underlying mechanism may be due to the overactive immune state that appears in the atopic conditions, which eliminates precancerous cells by increasing immune monitoring (39).
Several demographic characteristics and lifestyle-related factors are suspected of affecting the incidence of glioma. A study covering 99.9% of the U.S. population revealed that the incidence and survival rates of most glioma subtypes vary significantly depending on race or ethnicity, among which non-Hispanic whites have the highest incidence and the lowest survival rate (3, 5). The reason for this difference involves the variation in genetic risk susceptibility, access to health care, and socioeconomic status (SES). Another study based on CBTRUS data found glioma incidence in high SES counties was higher than in low SES counties (13). Ai Seon Kuan et al. summarized 3 large prospective studies and found that major food groups, nutrients, or common healthy dietary patterns were not associated with glioma incidence (40). Similar results have been observed in cigarette smoking and alcohol intake (41).

### TABLE 3 | Trends in Glioma Incidence-Based Mortality Ratesa (1995-2018): the SEER-9 registry database.

| Characteristic                                                                 | APC (95%CI)            | P Value |
|-------------------------------------------------------------------------------|------------------------|---------|
| **Overall**                                                                   | -0.4 (-0.6 to -0.2)    | <.001   |
| **Sex**                                                                       |                        |         |
| Male                                                                          | -0.3 (-0.6 to -0.1)    | 0.018   |
| Female                                                                        | -0.5 (-0.8 to -0.2)    | 0.001   |
| **Race**                                                                      |                        |         |
| White                                                                         | -0.2 (-0.4 to -0.1)    | 0.013   |
| Black                                                                         | 0.0 (-0.6 to 0.7)      | 0.902   |
| Otherb                                                                        | -0.1 (-0.8 to 0.6)     | 0.815   |
| **Age at Diagnosis/Death, y**                                                 |                        |         |
| <20                                                                           | 0.0 (-0.9 to 1.0)      | 0.932   |
| 20-39                                                                         | -0.9 (-1.5 to -0.2)    | 0.014   |
| 40-59                                                                         | -1.0 (-1.3 to -0.7)    | <.001   |
| 60-79                                                                         | -0.3 (-0.6 to -0.1)    | 0.010   |
| ≥80                                                                           | 1.0 (0.4 to 1.6)       | 0.001   |
| **Median Household Income**                                                   |                        |         |
| <75000                                                                        | 1.1 (0.6 to 1.6)       | <.001   |
| ≥75000                                                                        | -1.6 (-2.2 to -1.0)    | <.001   |
| **Rural-Urban**                                                               |                        |         |
| Urban                                                                         | 0.2 (0.0 to 0.4)       | 0.059   |
| Rural                                                                         | -1.4 (-1.9 to -0.9)    | <.001   |
| **Histologic Type**                                                           |                        |         |
| Glioblastoma                                                                  | 0.1 (-0.1 to 0.3)      | 0.188   |
| Non-glioblastoma astrocytoma                                                  | -2.1 (-2.6 to -1.5)    | <.001   |
| Oligodendroglial tumors                                                       | -0.5 (-1.5 to 0.6)     | 0.391   |
| Ependymoma                                                                    | 0.4 (-0.8 to 1.6)      | 0.527   |
| Glioma, NOS                                                                   | -1.0 (-1.8 to -0.2)    | 0.013   |
| **WHO Grade**                                                                 |                        |         |
| I                                                                             | NRd                    |         |
| II                                                                            | -2.0 (-2.5 to -1.6)    | <.001   |
| III                                                                           | -0.3 (-1.2 to 0.8)     | 0.512   |
| IV                                                                            | 0.1 (-0.1 to 0.3)      | 0.188   |
| Unknown                                                                       | -0.9 (-1.7 to -0.1)    | 0.038   |
| **Glioblastoma**                                                              |                        |         |
| Tumor Extension** (1995-2015)                                                 |                        |         |
| Localized                                                                     | 0.5 (0.2 to 0.7)       | 0.001   |
| Regional                                                                      | 0.5 (-0.3 to 1.4)      | 0.191   |
| Distant                                                                       | NRd                    |         |
| Unknown                                                                       | -4.6 (-6.2 to -2.9)    | <.001   |
| Tumor size, cm                                                                |                        |         |
| ≤3.0                                                                          | 1.8 (1.2 to 2.4)       | <.001   |
| >3.0 to ≤5.0                                                                  | 1.7 (1.3 to 2.1)       | <.001   |
| >5.0                                                                          | 3.1 (2.4 to 3.8)       | <.001   |
| Unknown                                                                       | -5.5 (-6.1 to -4.9)    | <.001   |

aRates were calculated as number of deaths per 100,000 person-years and age-adjusted to the 2000 US standard population.
bBased on deaths during 1995-2018 and cases diagnosed during 1975-2018.
Includes American Indian/Alaskan Native and Asian/Pacific Islander.
APC could not be calculated because there were 0 death in one or more years.
Tumor extension was based on cases diagnosed between 1983 and 2015.
Tumor size was based on cases diagnosed between 1983 and 2018.
SEER, Surveillance, Epidemiology, and End Results; APC, annual percent change; NOS, Not otherwise specified; WHO, World Health Organization.
by the decrease in incidence rate in recent years. Only those over 80 years of age have continued to experience an increase in mortality rate, possibly because of the increasing incidence of elderly patients as a result of an aging population. Furthermore, our results show that the significant decrease in the non-glioblastoma astrocytoma mortality rate contributed most to the overall mortality trend of glioma. Continuous improvement of diagnosis and treatment standards for patients with non-glioblastoma astrocytoma and precise management benefit low-grade glioma patients (42). As the incidence of glioblastoma continues to increase, the relatively stable mortality rates suggest that aggressive treatment methods, including surgery, radiotherapy, and chemotherapy, are effective for this highly malignant tumor. Especially since 2005, temozolomide has been widely used in the chemotherapy of glioblastoma. The survival rate of glioblastoma patients has been effectively improved (43). Our analysis of relative survival rates also supported this. It was found that the 5-year survival rate of glioblastoma patients increased obviously in 2004 and remained above 5% for a period of time thereafter. But the mortality rate did not show a significant downward trend around 2005. Tumor-treating fields (TTFields) is an emerging alternative treatment method, which combined with temozolomide chemotherapy can significantly prolong the survival of patients with glioblastoma (44). In addition, numerous clinical trials (45) of drugs targeting specific molecular markers for glioblastoma are underway, with no clear efficacy. The development of novel treatment sites and strategies are necessary.

We provide a comprehensive assessment of glioma incidence and mortality in the United States from 1975 to 2018 but must admit that there are several important limitations in this study. Due to the retrospective nature of this study, the accuracy of our results depends on the quality and availability of the SEER database. Individual-level risk factors, lifestyle habits, occupational exposure, and changes in glioma examination methods have not been recorded by registries. We can only speculate on possible explanations based on actual observed trends in glioma incidence and mortality. In addition, tumor extension and tumor size data were limited to the years in which the registries recorded, starting in 1983. And there were a large number of unknown values of these two indicators in the early recording period, and they decreased significantly with the years, especially the tumor size. It will lead us to overestimate the incidence and mortality rates we observe for known tumor extension and tumor size. Isocitrate dehydrogenase 1/2 mutation and 1p/19q codeletion were used for the classification of gliomas in the 2016 World Health Organization classification of tumors of the central nervous system (46). The SEER database did not record the information of these two molecules before 2018, so we did not include them in the analysis. Glioma incidence and mortality in the larger population need to be monitored to see if this trend is sustained.

### CONCLUSION

During 1975-2018, the incidence of glioma remained stable on the whole, but a significant decline in incidence was found from 1987 to 2018. Epidemiological changes in non-glioblastoma astrocytoma contributed the most to overall trends in glioma incidence and mortality. Trends in glioma incidence and mortality vary significantly by tumor characteristics. These findings can improve understanding of risk factors and guide the focus of glioma treatment.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Suppimentary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

The conception and design of the work, DL, MW, and SW. The acquisition, analysis, and interpretation of data, YC, JG, LC, XS, FL, ZC, and TX. Drafting the manuscript, DL, MW, and YC. Revising the manuscript, HS and SW. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70:7–30. doi: 10.3322/caac.21590
2. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21: v1–v100. doi: 10.1093/neuonc/noz150
3. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global Incidence of Malignant Brain and Other Central Nervous System Tumors by Histology, 2003-2007. Neuro Oncol (2017) 19:1553–64. doi: 10.1093/neo/neo091
4. Nakamura H, Makino K, Yano S, Kuratsu JK, Kumamoto Brain Tumor Research Group. Epidemiological Study of Primary Infranartral Tumors: A Regional Survey in Kumamoto Prefecture in Southern Japan—20-Year Study. Int J Clin Oncol (2011) 16:314–21. doi: 10.1007/s10147-010-0178-y
5. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2002 to 2014. JAMA Oncol (2018) 4:1254–62. doi: 10.1001/jamaoncol.2018.1789
6. National Cancer Institute, Surveillance, Epidemiology and End Results Program. SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2020 Sub (1975-2018) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total Us, 1969-2019 Counties. National Cancer Institute, DCCPS, Surveillance Research Program (2021).
7. National Cancer Institute, Surveillance, Epidemiology and End Results Program. SEER*Stat Database: Incidence-Based Mortality—SEER 9 Regs Research Data, Nov 2020 Sub (1975-2018) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total Us, 1969-2019 Counties. National Cancer Institute, DCCPS, Surveillance Research Program (2021).
8. Cho H, Howlader N, Mariotto AB, Cronin KA. Estimating Relative Survival for Cancer Patients From the SEER Program Using Expected Rates Based on Ederer I Versus Ederer II Method. Surveillance Research Program, NCI, Technical Report (2011).
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol (2007) 114:97–109. doi: 10.1007/s00401-007-0243-4
10. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation Tests for Joinpoint Regression With Applications to Cancer Rates. Stat Med (2000) 19:335–51. doi: 10.1002/1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
11. Kim SU, Aha S, Lee JE, Han KD, Park SH, Yang SH. Epidemiological Study of Malignant Gliomas in Korea Using Nationwide Dataset From 2007 to 2017. J Korean Med Sci (2021) 36:e68. doi: 10.3346/jkms.2021.36.668
12. Davis FG, Smith TR, Gittleman HR, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Glioblastoma Incidence Rate Trends in Canada and the United States Compared With England, 1995-2015. Neuro Oncol (2020) 22:301–2. doi: 10.1093/neuonc/noz203
13. Cote DJ, Ostrom QT, Gittleman H, Duncan KR, CreveCOeur TS, Kruchko C, et al. Glioma Incidence and Survival Variations by County-Level Socioeconomic Measures. Cancer (2019) 125:3390–400. doi: 10.1002/cncr.32328

FUNDING

This study was funded by Key Research and Development Project of Zhejiang Provincial Department of Science and Technology (Grant No. 2021C03105) and Natural Science Foundation of Zhejiang Province (Grant No. Y21H090041).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.748061/full#supplementary-material
28. Hepworth SJ, Schoemaker MJ, Muir KR, Swerdlow AJ, van Tongeren MJ, McKinney PA. Mobile Phone Use and Risk of Glioma in Adults: Case-Control Study. Br J Cancer (2009) 100:332–8. doi: 10.1038/sj.bjc.6605452

29. Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, et al. Mobile Phone Use and Glioma Risk: Comparison of Epidemiological Studies With Incidence Trends in the United States. BMJ (2012) 344:e1147. doi: 10.1136/bmj.e1147

30. Parent ME, Turner MC, Lavoue J, Richard H, Figuerola J, Kinc I, et al. Lifetime Occupational Exposure to Metals and Welding Fumes, and Risk of Glioma: A 7-Country Population-Based Case-Control Study. Environ Health (2017) 16:90. doi: 10.1186/s12940-017-0300-y

31. Neta G, Stewart PA, Rajaraman P, Hein MJ, Waters MA, Purdue MP, et al. Occupational Exposure to Chlorinated Solvents and Risks of Glioma and Meningioma in Adults. Occup Environ Med (2012) 69:793–801. doi: 10.1136/oemed-2012-100742

32. Ilyasova D, McCarthy B, Marcello J, Schildkraut JM, Moorman PG, Krishnamachari B, et al. Association Between Glioma and History of Allergies, Asthma, and Eczema: A Case-Control Study With Three Groups of Controls. Cancer Epidemiol Biomarkers Prev (2009) 18:1232–8. doi: 10.1158/1055-9965.EPI-08-0995

33. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR. History of Allergies and Risk of Glioma in Adults. Int J Cancer (2006) 119:2163–72. doi: 10.1002/ijc.22091

34. Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, Doss H, et al. Polymorphisms Associated With Asthma Are Inversely Related to Glioblastoma. Cancer Res (2005) 65:6459–65. doi: 10.1158/0008-5472.CAN-04-3728

35. Cahoon EK, Inskip PD, Gridley G, Brenner AV. Immune-Related Conditions and Subsequent Risk of Brain Cancer in a Cohort of 4.5 Million Male US Veterans. Br J Cancer (2014) 110:1825–33. doi: 10.1038/bjc.2014.97

36. Linos E, Raine T, Alonso A, Michaud D. Atopy and Risk of Brain Tumors: A Meta-Analysis. J Natl Cancer Inst (2007) 99:1544–50. doi: 10.1093/jnci/djm170

37. Schlehoffer B, Blettner M, Preston-Martin S, Niehoff D, Wahrenbrand J, Arslan A, et al. Role of Medical History in Brain Tumour Development. Results From the International Adult Brain Tumour Study. Int J Cancer (1999) 82:155–60. doi: 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P

38. McCarthy BJ, Rankin K, Ilyasova D, Erdal S, Vick N, Ali-Osman F, et al. Assessment of Type of Allergy and Antihistamine Use in the Development of Glioma. Cancer Epidemiol Biomarkers Prev (2011) 20:370–8. doi: 10.1158/1055-9965.EPI-10-0948

39. Davis FG, Al-Alem U. Allergies and Adult Gliomas: Cohort Results Strengthen Evidence for a Causal Association. J Natl Cancer Inst (2011) 103:1562–3. doi: 10.1093/jnci/djr397

40. Kuan AS, Green J, Kitahara CM, De Gonzalez AB, Key T, KR G, et al. Diet and Risk of Glioma: Combined Analysis of 3 Large Prospective Studies in the UK and USA. Neuro Oncol (2019) 21:944–52. doi: 10.1093/neuonc/noz013

41. Braganza MZ, Rajaraman P, Park Y, Inskip PD, Freedman ND, Hollebeck AR, et al. Cigarette Smoking, Alcohol Intake, and Risk of Glioma in the NIH-AARP Diet and Health Study. Br J Cancer (2014) 110:242–8. doi: 10.1038/bjc.2013.611

42. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw (2017) 15:1331–45. doi: 10.6004/jnccn.2017.0166

43. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med (2005) 352:987–96. doi: 10.1056/NEJMoa043330

44. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA (2015) 314:2535–43. doi: 10.1001/jama.2015.16669

45. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma Targeted Therapy: Updated Approaches From Recent Biological Insights. Ann Oncol (2017) 28:1457–72. doi: 10.1093/annonc/mdx106

46. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.